Jardiance

Empagliflozin, the active ingredient in Jardiance, is a Sodium‑glucose co‑transporter 2 (SGLT2) inhibitor presented as a tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, to lower cardiovascular death in those with established cardiovascular disease, and to treat heart failure with reduced ejection fraction.

GNH USA supplies Jardiance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing regulated distribution to qualified healthcare institutions.

Jardiance, an SGLT2 inhibitor, is used in several metabolic and cardiovascular conditions. - Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Cardiovascular disease in adults with type 2 diabetes: lowers risk of cardiovascular death. - Heart failure with reduced ejection fraction: decreases cardiovascular death and heart‑failure hospitalisation.

Empagliflozin may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Genital mycotic infection: increased risk of yeast infections. - Urinary tract infection: symptoms of dysuria or frequency. - Increased urination: polyuria leading to nocturia. - Thirst: heightened fluid intake. - Hypotension: especially in patients on diuretics. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Diabetic ketoacidosis: metabolic acidosis with normal or low glucose. - Acute kidney injury: sudden decline in renal function. - Severe dehydration: due to excessive fluid loss. - Fournier's gangrene: necrotizing fasciitis of the perineum. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hypoglycaemia: when combined with insulin or insulin secretagogues.

When prescribing empagliflozin, clinicians should consider several safety aspects. - Renal function monitoring: avoid in patients with severe renal impairment. - Volume depletion risk: assess hydration status, especially in the elderly. - Ketoacidosis vigilance: educate patients on signs of euglycaemic ketoacidosis. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Concomitant diuretics: monitor for additive hypotensive effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Empagliflozin can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Insulin or insulin secretagogues: increased risk of hypoglycaemia. - Loop diuretics: may exacerbate volume depletion. - Other SGLT2 inhibitors: duplicate pharmacologic effect.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: additive blood‑pressure lowering. - NSAIDs: potential impact on renal function. - Rifampin: may reduce empagliflozin exposure. - Thiazide diuretics: further diuretic effect.